Stefanie Kraff1, Andreas Lindauer, Markus Joerger, Salvatore J Salamone, Ulrich Jaehde. 1. *Department of Clinical Pharmacy, Institute of Pharmacy, University of Bonn, Germany; †SGS Exprimo NV, Mechelen, Belgium; ‡Department of Oncology & Hematology, Cantonal Hospital, St. Gallen, Switzerland; and §Saladax Biomedical Inc, Bethlehem, Pennsylvania.
Abstract
BACKGROUND: Neutropenia is a frequent and severe adverse event in patients receiving paclitaxel chemotherapy. The time above a paclitaxel threshold concentration of 0.05 μmol/L (Tc > 0.05 μmol/L) is a strong predictor for paclitaxel-associated neutropenia and has been proposed as a target pharmacokinetic (PK) parameter for paclitaxel therapeutic drug monitoring and dose adaptation. Up to now, individual Tc > 0.05 μmol/L values are estimated based on a published PK model of paclitaxel by using the software NONMEM. Because many clinicians are not familiar with the use of NONMEM, an Excel-based dosing tool was developed to allow calculation of paclitaxel Tc > 0.05 μmol/L and give clinicians an easy-to-use tool. METHODS: Population PK parameters of paclitaxel were taken from a published PK model. An Alglib VBA code was implemented in Excel 2007 to compute differential equations for the paclitaxel PK model. Maximum a posteriori Bayesian estimates of the PK parameters were determined with the Excel Solver using individual drug concentrations. Concentrations from 250 patients were simulated receiving 1 cycle of paclitaxel chemotherapy. Predictions of paclitaxel Tc > 0.05 μmol/L as calculated by the Excel tool were compared with NONMEM, whereby maximum a posteriori Bayesian estimates were obtained using the POSTHOC function. RESULTS: There was a good concordance and comparable predictive performance between Excel and NONMEM regarding predicted paclitaxel plasma concentrations and Tc > 0.05 μmol/L values. Tc > 0.05 μmol/L had a maximum bias of 3% and an error on precision of <12%. The median relative deviation of the estimated Tc > 0.05 μmol/L values between both programs was 1%. CONCLUSIONS: The Excel-based tool can estimate the time above a paclitaxel threshold concentration of 0.05 μmol/L with acceptable accuracy and precision. The presented Excel tool allows reliable calculation of paclitaxel Tc > 0.05 μmol/L and thus allows target concentration intervention to improve the benefit-risk ratio of the drug. The easy use facilitates therapeutic drug monitoring in clinical routine.
BACKGROUND:Neutropenia is a frequent and severe adverse event in patients receiving paclitaxel chemotherapy. The time above a paclitaxel threshold concentration of 0.05 μmol/L (Tc > 0.05 μmol/L) is a strong predictor for paclitaxel-associated neutropenia and has been proposed as a target pharmacokinetic (PK) parameter for paclitaxel therapeutic drug monitoring and dose adaptation. Up to now, individual Tc > 0.05 μmol/L values are estimated based on a published PK model of paclitaxel by using the software NONMEM. Because many clinicians are not familiar with the use of NONMEM, an Excel-based dosing tool was developed to allow calculation of paclitaxelTc > 0.05 μmol/L and give clinicians an easy-to-use tool. METHODS: Population PK parameters of paclitaxel were taken from a published PK model. An Alglib VBA code was implemented in Excel 2007 to compute differential equations for the paclitaxel PK model. Maximum a posteriori Bayesian estimates of the PK parameters were determined with the Excel Solver using individual drug concentrations. Concentrations from 250 patients were simulated receiving 1 cycle of paclitaxel chemotherapy. Predictions of paclitaxelTc > 0.05 μmol/L as calculated by the Excel tool were compared with NONMEM, whereby maximum a posteriori Bayesian estimates were obtained using the POSTHOC function. RESULTS: There was a good concordance and comparable predictive performance between Excel and NONMEM regarding predicted paclitaxel plasma concentrations and Tc > 0.05 μmol/L values. Tc > 0.05 μmol/L had a maximum bias of 3% and an error on precision of <12%. The median relative deviation of the estimated Tc > 0.05 μmol/L values between both programs was 1%. CONCLUSIONS: The Excel-based tool can estimate the time above a paclitaxel threshold concentration of 0.05 μmol/L with acceptable accuracy and precision. The presented Excel tool allows reliable calculation of paclitaxelTc > 0.05 μmol/L and thus allows target concentration intervention to improve the benefit-risk ratio of the drug. The easy use facilitates therapeutic drug monitoring in clinical routine.
Authors: Daniel L Hertz; Kelley M Kidwell; Kiran Vangipuram; Feng Li; Manjunath P Pai; Monika Burness; Jennifer J Griggs; Anne F Schott; Catherine Van Poznak; Daniel F Hayes; Ellen M Lavoie Smith; N Lynn Henry Journal: Clin Cancer Res Date: 2018-04-27 Impact factor: 12.531
Authors: Yongzhen Chen; Fang Fang; Kelley M Kidwell; Kiran Vangipuram; Lauren A Marcath; Christina L Gersch; James M Rae; Daniel F Hayes; Ellen M Lavoie Smith; N Lynn Henry; Andreas S Beutler; Daniel L Hertz Journal: Pharmacogenomics Date: 2020-07-23 Impact factor: 2.533
Authors: Daniel L Hertz; Li Chen; N Lynn Henry; Jennifer J Griggs; Daniel F Hayes; Brian A Derstine; Grace L Su; Stewart C Wang; Manjunath P Pai Journal: Br J Clin Pharmacol Date: 2022-02-14 Impact factor: 3.716
Authors: Lauren A Marcath; Kelley M Kidwell; Kiran Vangipuram; Christina L Gersch; James M Rae; Monika L Burness; Jennifer J Griggs; Catherine Van Poznak; Daniel F Hayes; Ellen M Lavoie Smith; N Lynn Henry; Andreas S Beutler; Daniel L Hertz Journal: Br J Clin Pharmacol Date: 2020-02-04 Impact factor: 4.335
Authors: Li Chen; Ciao-Sin Chen; Yihan Sun; N Lynn Henry; Kathleen A Stringer; Daniel L Hertz Journal: Cancer Chemother Pharmacol Date: 2021-06-05 Impact factor: 3.288
Authors: Ka Ho Matthew Hui; Chung Yan Grace Lui; Ka Lun Alan Wu; Jason Chen; Yin Ting Cheung; Tai Ning Teddy Lam Journal: PLoS One Date: 2022-05-05 Impact factor: 3.752